Researchers in Japan are set to conduct clinical trials for a tooth regrowth medicine targeting congenital anodontia patients by deactivating the USAG-1 protein to allow tooth development.
Toregem Biopharma's treatment aims to provide a new option for those lacking teeth, moving beyond implants and dentures as a potential solution.
Successful trials in animals, such as ferrets, have shown promising results in growing new teeth without side effects, instilling hope for similar success in human trials.
[
add
]
[
|
|
...
]